The long-term trend of the EPS is an important number as it indicates the present value of Ironwood Pharmaceuticals. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 4.10 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Ironwood Pharmaceuticals is making for it’s investors or shareholders.
Ironwood Pharmaceuticals is part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Peter M. Hecht. Ironwood Pharmaceuticals Inc is a biotechnology company which is focused on advancing innovative product opportunities in areas of large unmet needs such as constipation, gastrointestinal disorders, hyperuricemia, among others.
Previous Intraday Performance:
The IRWD shares had a previous change of -7.83% which opened at 13.77 and closed at 12.72. It moved to an intraday high of 14.00 and a low of 12.68.
Over the last five trading days, IRWD shares returned -8.29% and in the past 30 trading days it returned -23.05%. Over three months, it changed -31.24%. In one year it has changed -21.67% and within that year its 52-week high was 21.20 and its 52-week low was 11.02. IRWD stock is 15.43% above its 52 Week Low.
Our calculations result in a 200 day moving average of 17.00 and a 50 day moving average of 15.12. Right now, IRWD stock is trading -25.18% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $2.0b with 154.1m shares outstanding and a float of 146.1m shares. Trading volume was 1,996,519 shares and has experienced an average volume of 1,761,415 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Ironwood Pharmaceuticals was -0.79 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.14.
Below was the last reported quarterly earnings per share:
Base on our calculations, the intrinsic value per share is 2.53, which means it might overvalued by -402.60%
Indicators Also to Watch:
Based on the latest filings, there is 151.80% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.29
Based on last reported financials, the company’s return on assets is -49.22%, profit margin is -83.26%, price-to-sales is 6.92 and price-to-book is 279.57.
Company Score Card:
Results are out of six:
4 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result